(AOF) – “Detailed positive results from a second phase III trial showed that treatment with Dupixent (dupilumab) 300mg once weekly significantly improved signs and symptoms of eosinophilic esophagitis at 24 weeks , compared to placebo, in patients 12 years of age and older,” Sanofi said. These pivotal data were presented this weekend at the 2022 Congress of the American Academy of Allergy, Asthma and Immunology, during a late-breaking abstract session.
Eosinophilic esophagitis is a chronic, progressive disease with a type 2 inflammatory signature that impairs the esophagus and its functioning.
The pharmaceutical group points out that Dupixent 300 mg once a week is the only biologic drug that has shown positive, clinically significant phase III results in adults and adolescents suffering from this disease.
Evan S. Dellon, MD, MPH, Professor of Gastroenterology and Hepatology at the University of North Carolina School of Medicine and co-principal investigator of the trial said “Eosinophilic esophagitis can have serious affect the ability to eat normally and require doctors to use invasive medical procedures to monitor and, in the most severe cases, dilate the esophagus.There are currently no FDA-approved treatment options to remedy to the underlying causes of this disease.Data from this trial shows that Dupixent once weekly not only improves swallowing, but also decreases markers of type 2 inflammation in the esophagus, indicating its potential to address one of the major underlying causes of eosinophilic esophagitis.”
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.